Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Botox Sweating Indication Launch Will Focus On Formulary Reimbursement

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan's launch of Botox' excessive sweating indication will center on gaining formulary access

You may also be interested in...



Botox Managed Care Coverage On The Rise Following Flat Quarter, Allergan Says

Allergan is pointing to positive managed care coverage for Botox as positive news in light of sequentially flat growth for the product

Botox Managed Care Coverage On The Rise Following Flat Quarter, Allergan Says

Allergan is pointing to positive managed care coverage for Botox as positive news in light of sequentially flat growth for the product

Allergan Restasis DTC Campaign Will Begin Shortly

The TV and print ad campaign for the dry eye therapy will target the over-50 population and women, Allergan says. The company remains comfortable with the price and reimbursement support for Restasis.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel